Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals

Diabetes and Vascular Disease Research

Volumn 13, Issue 6, 2016, Pages 438-441

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; sodium glucose cotransporter 2; tofogliflozin; tubular injury

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CREATININE; GLUCOSE; LACTATE DEHYDROGENASE; N ACETYL BETA GLUCOSAMINIDASE; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ACETYLGLUCOSAMINIDASE; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; EARLY DIAGNOSIS; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEART RATE; HYPERGLYCEMIA; KIDNEY INJURY; KIDNEY MASS; MALE; MICROALBUMINURIA; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CELL PROTECTION; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; URINE;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; ANIMALS; BENZHYDRYL COMPOUNDS; BIOMARKERS; BLOOD GLUCOSE; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GLUCOSIDES; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MICE, INBRED C57BL; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84991721018     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164116657304     Document Type: Article

References (12)

1. IDF diabetes atlas. 7th ed., http://www.diabetesatlas.org (2016,. accessed 6 January 2016).
2. Yamagishi S, Matsui T,. Protective role of sodium-glucose co-transporter 2 inhibition against vascular complications in diabetes. Rejuvenation Res 2016; 19: 107-114.
3. Ziyadeh FN, Goldfarb S,. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 464-475.
4. Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051.
5. Ishibashi Y, Matsui T, Yamagishi S,. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res 2016; 48: 191-195.
6. Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 2015; 47: 686-692.
7. Fu WJ, Xiong SL, Fang YG, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012; 41: 82-88.
8. Mise K, Hoshino J, Ueno T, et al. Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-d-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. Clin J Am Soc Nephrol 2016; 11: 593-601.
9. Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 2013; 170: 519-531.
10. Schwab D, Portron A, Backholer Z, et al. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet 2013; 52: 463-473.
11. Maeda S, Matsui T, Takeuchi M, et al. Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis. Diabetes Metab Res Rev 2013; 29: 406-412.
12. Kern EF, Erhard P, Sun W, et al. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis 2010; 55: 824-834.